Literature DB >> 17988078

A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Lin Li1, James Bading, Paul J Yazaki, Amitkumar H Ahuja, Desiree Crow, David Colcher, Lawrence E Williams, Jeffrey Y C Wong, Andrew Raubitschek, John E Shively.   

Abstract

Radiolabeled anti-carcinoembryonic antigen (CEA) antibodies have the potential to give excellent images of a wide variety of human tumors, including tumors of the colon, breast, lung, and medullar thyroid. In order to realize the goals of routine and repetitive clinical imaging with anti-CEA antibodies, it is necessary that the antibodies have a high affinity for CEA, low cross reactivity and uptake in normal tissues, and low immunogenicity. The humanized anti-CEA antibody hT84.66-M5A (M5A) fulfills these criteria with an affinity constant of >10 (10) M (-1), no reactivity with CEA cross-reacting antigens found in normal tissues, and >90% human protein sequence. A further requirement for routine clinical use of radiolabeled antibodies is a versatile method of radiolabeling that allows the use of multiple radionuclides that differ in their radioemissions and half-lives. We describe a versatile bifunctional chelator, DO3A-VS (1,4,7-tris(carboxymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclododecane) that binds a range of radiometals including 111 In for gamma-ray imaging and 64Cu for positron emission tomography (PET), and which can be conjugated with negligible loss of immunoreactivity either to sulfhydryls (SH) in the hinge region of lightly reduced immunoglobulins or surface lysines (NH) of immunoglobulins. Based on our correlative studies comparing the kinetics of radiolabeled anti-CEA antibodies in murine models with those in man, we predict that 64Cu-labeled intact, humanized antibodies can be used to image CEA positive tumors in the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988078      PMCID: PMC2553277          DOI: 10.1021/bc700161p

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  25 in total

Review 1.  The promise of immuno-PET in radioimmunotherapy.

Authors:  Iris Verel; Gerard W M Visser; Guus A van Dongen
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 2.  Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.

Authors:  O A Gansow
Journal:  Int J Rad Appl Instrum B       Date:  1991

3.  Selective reduction and proteolysis in the hinge region of liganded and unliganded antibodies: identical kinetics suggest lack of major conformational change in the hinge region.

Authors:  J K Wright; J Engel; J C Jaton
Journal:  Eur J Immunol       Date:  1978-05       Impact factor: 5.532

Review 4.  Pathogenesis of IgA nephropathy.

Authors:  J Feehally; A C Allen
Journal:  Ann Med Interne (Paris)       Date:  1999-02

5.  In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Authors:  Russell J Sanderson; Michelle A Hering; Stephanie F James; Michael M C Sun; Svetlana O Doronina; Anthony W Siadak; Peter D Senter; Alan F Wahl
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

6.  Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS.

Authors:  C Andrew Boswell; Paul McQuade; Gary R Weisman; Edward H Wong; Carolyn J Anderson
Journal:  Nucl Med Biol       Date:  2005-01       Impact factor: 2.408

7.  A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.

Authors:  D L Kukis; H Diril; D P Greiner; S J DeNardo; G L DeNardo; Q A Salako; C F Meares
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

8.  Humanization of the anti-CEA T84.66 antibody based on crystal structure data.

Authors:  Paul J Yazaki; Mark A Sherman; John E Shively; David Ikle; Lawrence E Williams; Jeffrey Y C Wong; David Colcher; Anna M Wu; Andrew A Raubitschek
Journal:  Protein Eng Des Sel       Date:  2004-08-17       Impact factor: 1.650

9.  Labeling of immunoglobulins with bifunctional, sulfhydryl-selective, and photoreactive coumarins.

Authors:  J Baranowska-Kortylewicz; A I Kassis
Journal:  Bioconjug Chem       Date:  1993 Jul-Aug       Impact factor: 4.774

10.  Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in pichia pastoris. The essential role of the N-domain.

Authors:  Y H You; L J Hefta; P J Yazaki; A M Wu; J E Shively
Journal:  Anticancer Res       Date:  1998 Sep-Oct       Impact factor: 2.480

View more
  21 in total

1.  Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.

Authors:  Thomas S C Ng; James R Bading; Ryan Park; Hargun Sohi; Daniel Procissi; David Colcher; Peter S Conti; Simon R Cherry; Andrew A Raubitschek; Russell E Jacobs
Journal:  J Nucl Med       Date:  2012-06-01       Impact factor: 10.057

2.  Positive progress in immunoPET--not just a coincidence.

Authors:  Katelyn E McCabe; Anna M Wu
Journal:  Cancer Biother Radiopharm       Date:  2010-06       Impact factor: 3.099

3.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

4.  Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Authors:  Joanne E Mortimer; James R Bading; David M Colcher; Peter S Conti; Paul H Frankel; Mary I Carroll; Shan Tong; Erasmus Poku; Joshua K Miles; John E Shively; Andrew A Raubitschek
Journal:  J Nucl Med       Date:  2013-12-12       Impact factor: 10.057

5.  Prototype Small-Animal PET-CT Imaging System for Image-guided Radiation Therapy.

Authors:  Ekaterina Mikhaylova; Jamison Brooks; Darren Zuro; Farouk Nouizi; Maciej Kujawski; Srideshikan Sargur Madabushi; Jinyi Qi; Mengxi Zhang; Junie Chea; Erasmus K Poku; Nicole Bowles; Jeffrey Y C Wong; John E Shively; Paul J Yazaki; Gultekin Gulsen; Simon R Cherry; Susanta Hui
Journal:  IEEE Access       Date:  2019-09-30       Impact factor: 3.367

6.  Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.

Authors:  Arutselvan Natarajan; Gayatri Gowrishankar; Carsten H Nielsen; Sen Wang; Andrei Iagaru; Michael L Goris; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

7.  Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.

Authors:  Lin Li; Fabio Turatti; Desiree Crow; James R Bading; Anne-Line Anderson; Erasmus Poku; Paul J Yazaki; Lawrence E Williams; Debra Tamvakis; Paul Sanders; David Leong; Andrew Raubitschek; Peter J Hudson; David Colcher; John E Shively
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

Review 8.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

9.  Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.

Authors:  James R Bading; Magnus Hörling; Lawrence E Williams; David Colcher; Andrew Raubitschek; Sven E Strand
Journal:  Cancer Biother Radiopharm       Date:  2008-08       Impact factor: 3.099

10.  Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen.

Authors:  Hao Hong; Jiangtao Sun; Weibo Cai
Journal:  Biomark Insights       Date:  2008-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.